Supernus Pharmaceuticals | SUPN - Cash And Equivalent


Supernus Pharmaceuticals reported $179.95M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
ANI Pharmaceuticals USD 360.21M 49.04M Jun/2026
Aurora Cannabis CAD 64.69M 8.33M Mar/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Canopy Growth CAD 364.68M 6.64M Mar/2026
Cara Therapeutics USD 19.85M 883K Mar/2026
Corcept Therapeutics USD 111.04M 2.3M Jun/2026
Eisai JPY 245.42B 56.22B Mar/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Pacira USD 205.88M 61.57M Jun/2026
Perrigo USD 357.2M 174.4M Mar/2026
Pfizer USD 976M 727M Jun/2026
Supernus Pharmaceuticals USD 179.95M 4.92M Jun/2026
United Therapeutics USD 1.8B 523.5M Jun/2026
Xeris Pharmaceuticals USD 121.75M 10M Jun/2026